O. Koo

Biomaterials · 2005

A researcher in the Science corpus: 1 paper; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom O. Koo trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Mauro Ferrari
  2. B. Rabinow
  3. Indrajit Roy
  4. Benoit Dubertret
  5. S. Sahoo

Who trusts O. Koo overall

  1. Bambang Kuswandi

Papers from O. Koo's perspective

Ordered by how strongly the researchers O. Koo trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. (European Journal of Cancer)
  2. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. (Clinical Cancer Research)
  3. Nanocrystal targeting in vivo (Proceedings of the National Academy of Sciences of the United States of America)
  4. Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor (Pharmaceutical Research)
  5. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. (Journal of Controlled Release)
  6. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. (Progress in lipid research)
  7. Long-circulating and target-specific nanoparticles: theory to practice. (Pharmacological Reviews)
  8. Nanotech approaches to drug delivery and imaging. (Drug Discovery Today)
  9. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. (Clinical Cancer Research)
  10. Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies (Clinical Cancer Research)

Their papers